Uvax Bio, a privately held vaccine developer founded in 2018 as a spin-off from Scripps Research, has appointed chief business officer Kevin O’Neill as interim chief executive. Mr O’Neill, who joined ...
Maximize your negotiation outcomes with proven strategies from Kellogg faculty and global leaders. Whether the goal is to create a standalone solution or fashion part of a complex talent development ...
Sinch (Sinch AB (publ)) ? (XSTO: SINCH), which is pioneering the way the world communicates through its digital Customer Communications Cloud, today announced transformative updates to Sinch Mailjet, ...
Bio-Techne Corp (NASDAQ:TECH) reported stronger-than-expected earnings for the second quarter of fiscal year 2024, with adjusted earnings per share (EPS) of $0.42, surpassing the forecasted $0.39.
Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode and the call will ...
What place do stories of romance and marriage have in the pages of a newspaper? Join this conversation with the Vows writer Rosalie R. Radomsky by Feb. 14 to find out. By The Learning Network A ...
04, 2025 (GLOBE NEWSWIRE) -- Uvax Bio, LLC, (“Uvax” or “the Company ... Business Officer Kevin O’Neill to Interim Chief Executive Officer (CEO). Mr. O’Neill succeeds Ji Li, Ph.D ...